Market Research Logo

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Review, H1 2016

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Review, H1 2016’, provides in depth analysis on Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2)
  • The report reviews Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics
  • Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) Overview
Therapeutics Development
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Stage of Development
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Therapy Area
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Indication
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Companies
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Companies Involved in Therapeutics Development
CJ HealthCare Corp.
MorphoSys AG
Novartis AG
Vicore Pharma AB
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Drug Profiles
(amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EMA-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-6A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Dormant Projects
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Featured News & Press Releases
Feb 10, 2015: Spinifex Pharmaceuticals Enhances CMC Team With Two Senior Appointments
May 21, 2014: Lanthio Pharma receives Dutch Government loan of up to €3.6 million to develop novel therapy for lung fibrosis
Feb 05, 2014: Spinifex Pharmaceuticals’ Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia
Oct 18, 2013: Spinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch
Mar 27, 2013: Spinifex Pharma Receives AUD1.5m In R&D Tax Incentive For Research Activities Related To Discovery Of Treatments For Pain
Feb 18, 2013: Vicore Pharma Announces Publication Of Article In Nature
Dec 10, 2012: Spinifex Pharma Starts Phase II Proof-of-concept Trial Of EMA401 In Chemotherapy-induced Peripheral Neuropathy
Nov 15, 2012: Vicore Pharma Announces Presentation Of Study Results Of C21 In Pulmonary Hypertension At 2012 American Heart Meeting
Nov 15, 2012: Vicore Pharma Announces Publication Of Study Results Of C21 In Spinal Cord Injury In Journal Neurobiology Of Disease
Aug 28, 2012: Spinifex Pharma Announces Positive Phase II Results For EMA401 In Postherpetic Neuralgia
Sep 19, 2011: Spinifex Announces Start Of Phase II Proof-of-Concept Trial Of EMA401 In Postherpetic Neuralgia
Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting
Aug 23, 2011: Additional Funds To Broaden EMA401 Phase II Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by CJ HealthCare Corp., H1 2016
Pipeline by MorphoSys AG, H1 2016
Pipeline by Novartis AG, H1 2016
Pipeline by Vicore Pharma AB, H1 2016
Dormant Projects, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report